Aptevo Therapeutics Inc. buy geldnutzer
Summary
This prediction ended on 26.01.17 with a price of €25.76. The price of Aptevo Therapeutics Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -24.44%. geldnutzer has 50% into this predictionUnfortunately, there is no listed company called Aptevo Therapeutics with the symbol APVOV. However, there is a company with the symbol APVO. Aptevo Therapeutics is a biotechnology company that focuses on the discovery, development, and commercialization of novel oncology and hematology therapeutics. The company's product portfolio includes treatments for a variety of conditions such as hemophilia, immune disorders, and cancer. Their approach involves using genetically engineered proteins to target specific diseases and their therapies have shown promising results in clinical trials.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Aptevo Therapeutics Inc. | - | - | - | - |
iShares Core DAX® | 1.804% | -0.748% | 13.168% | 16.408% |
iShares Nasdaq 100 | -0.182% | -3.412% | 39.976% | 43.502% |
iShares Nikkei 225® | 0.413% | -7.381% | 18.776% | 2.874% |
iShares S&P 500 | 0.664% | -1.941% | 28.141% | 42.155% |
Comments by geldnutzer for this prediction
In the thread Aptevo Therapeutics Inc diskutieren
Im Biotechbereich interessant, es lohnt sich, wenn die Produkte positiv vermarktet werden.
Ich bin Ende des Jahres auf diesen Wert aufmerksam geworden, jetzt steigt die Aktie stark, jeder sollte sich eine Meinung bilden, aber die Aussichten sehen gut aus. Hier die News:
positive Studiendaten für seinen in Phase 2 befindlichen Wirkstoff Otlertuzumab.